Sana Biotechnology Inc (SANA) - News Archive

NEW YORK, April 12, 2025 Pomerantz LLP has announced the filing of a class action lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) and certain top executives amidst growing scrutiny surrounding the company’s fina...

The Stormy Waters of Biotechnology: Analyzing Sana Biotechnology’s Legal and Financial ChallengesIn recent months, the biotechnology sector has faced its fair share of turbulence, with Sana Biotechnology, Inc. (NASDAQ:...

Transformative Progress in Type 1 Diabetes: The Promise of Immunosuppression-Free Islet Cell Transplantation In a groundbreaking advancement for the treatment of Type 1 diabetes, Sana Biotechnology recently announced po...

Sana Biotechnology s Bold Gambit: Fast Tracking into the Future of Autoimmune Treatments Amid Financial TurbulenceBy CSI Market In a move that could reshape the landscape of autoimmune disease treatment, Sana Biotechnol...

: Sana Biotechnology has embarked on an ambitious initiative to leverage groundbreaking therapeutic platforms to address type 1 diabetes and B-cell mediated autoimmune diseases. As clinical trials edge closer, this arti...

In a significant step toward enhancing its innovative capabilities, Sana Biotechnology, Inc. (NASDAQ: SANA), a pioneering company dedicated to reshaping medical possibilities through engineered cells, has announced the...

In a recent publication in Nature Biotechnology, Sana Biotechnology has unveiled promising preclinical data showcasing the potential of pluripotent stem cell-derived human glial progenitor cell transplantation as a trea...

Sana Biotechnology s HIP-modified Cell Therapies Show Promising Results in Diabetes and Cancer TreatmentSEATTLE, Dec. 01, 2023 - Sana Biotechnology, a company dedicated to revolutionizing patient care through engineered...

Sana Biotechnology Announces Successful Completion of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional SharesSEATTLE, Feb. 12, 2024 - Sana Biotechnology, Inc. (Nasdaq: SANA), a pio...

Sana Biotechnology Sets New Course with Upsized Public OfferingIn a bold move that demonstrates its commitment to revolutionizing patient care, Sana Biotechnology, Inc. recently revealed the pricing details for its upsi...

Sana Biotechnology Inc. has achieved a great milestone by obtaining a clearance for their Investigational New Drug Application for SC262 from the U.S. Food and Drug Administration (FDA). This breakthrough is seen as a s...

Sana Biotechnology, a leading biotechnology company, presented groundbreaking preclinical data at the American Society of Hematology Annual Meeting, shedding light on the remarkable abilities of their hypoimmune-modifie...

Seattle-based biotechnology company, Sana Biotechnology, recently released positive preliminary clinical data regarding their novel allogeneic CAR T cell therapy, SC291. The study, known as ARDENT, is a Phase 1 clinical...